Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2023 · 10-Q
Revenue$677.48K$677.48K+45.2% vs Q1 2022 Net Income-$1.79M-$1.79MN/M vs Q1 2022 EPS Diluted-$0.12-$0.12N/M vs Q1 2022 Gross Profit$225,609+124.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flow-$313,851N/M Free Cash Flowderived-$329,071N/M Margins · derivedGross margin33.3%+11.8 pt vs Q1 2022
Operating margin-190.4%+162.9 pt vs Q1 2022
Net margin-264.4%+332.0 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end